Top Markets
#1 QuantixAI QuantixAI +33.28%
#2 Siren Siren +31.57%
#3 MowCat MowCat +27.77%
#4 Prom Prom +26.57%
#5 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +24.85%
#6 Tutorial Tutorial +20.89%
#7 UnifAI Network UnifAI Network +19.01%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +17.93%
#9 Versatize Coin Versatize Coin +16.67%
#10 Pons Pons +15.57%
Coin of the day
QuantixAI QuantixAI
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
ZIOPHARM Oncology, Inc. ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc.

ZIOP
Classifica tra le azioni #20769
ZIOPHARM Oncology, Inc. is a clinical-stage biopharmaceutical firm dedicated to... ZIOPHARM Oncology, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing innovative immuno-oncology treatments for cancer patients. The company leverages its proprietary Sleeping Beauty platform, which employs non-viral genetic engineering to modify T-cells outside the body using a transposon/transposase system for subsequent infusion. Additionally, ZIOPHARM is advancing its Controlled IL-12 technology, designed to precisely regulate the expression of interleukin-12 (IL-12), a key immune system regulator, to direct the patient's immune response against cancer cells. Its pipeline features several promising therapeutic candidates, including T-cell receptor (TCR) plus T-cell therapies aimed at solid tumors, chimeric antigen receptor (CAR) T-cell therapies specifically targeting CD19 for hematologic malignancies, and Ad-RTS-hIL-12 combined with veledimex, a gene delivery system for controlled IL-12 production under investigation for treating recurrent adult glioblastoma multiforme. ZIOPHARM maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., and research and development agreements, alongside patent licensing, with institutions such as The University of Texas MD Anderson Cancer Center and the National Cancer Institute. The company's headquarters are located in Boston, Massachusetts.
Prezzo delle azioni
$0.8657
Ultima sincronizzazione: 2022-01-26
Capitalizzazione di mercato
$122.22M
Variazione (1 giorno)
-0.88%
Variazione (1 anno)
0.00%
Paese
US
Scambia ZIOPHARM Oncology, Inc. (ZIOP)

Categoria

Healthcare
Utile per ZIOPHARM Oncology, Inc. (ZIOP)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di ZIOPHARM Oncology, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di ZIOPHARM Oncology, Inc. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH